Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Abstract

In this review, we discuss selected topics which are relevant to implementing precision medicine in metabolic disorders. Personalization of diet and exercise may help in preventing obesity and type 2 diabetes (T2D). Weight loss should be personalized based on age, sex, ethnicity, and coexisting comorbidities. Advances in our understanding of the pathophysiology, genetics, and epigenetics of obesity promise to offer tailored management options. Careful risk assessment is necessary prior to intervention. Risk may be underestimated, e.g., in women, in different ethnic groups, and in people with T2D. More personalized approaches could be useful among persons who failed to respond to traditional risk factor management, such as pharmacological treatment for dyslipidemia and arterial hypertension. Nonalcoholic fatty liver disease/metabolic-associated fatty liver disease (NAFLD/MAFLD) is both a cause and an effect of altered glucose and lipid metabolism. Personalized medicine approaches could be key to identify more effective pharmacological strategies as well as to reverse this common and burdensome metabolic liver disease. Finally, metabolomics could be used to identify relevant biomarkers for cancer diagnosis, staging, and prognostication. Cancers of the colon and rectum, breast, prostate, thyroid, and ovaries illustrate the notion that cancer cell metabolic derangements may be utilized in clinical practice. A true personalization of pharmacotherapies should be pursued especially in obese patients with cancer.

Keywords

Arterial hypertension / biomarkers / breast / cancer / cardiovascular risk / epigenetics / genetics / gut microbiota / MAFLD / management / metabolic syndrome / metabolomics / NAFLD / pathophysiology / personalized medicine / precision medicine / prevention / prostate / research / thyroid / type 2 diabetes

References

[1] Lonardo A.Editorial: metabolism and target organ damage.Metab Target Organ Damage2021;1:1

[2] Kelly T,Chen CS,He J.Global burden of obesity in 2005 and projections to 2030.Int J Obes (Lond)2008;32:1431-7

[3] Lonardo A,Arrese M.Perspectives on precision medicine approaches to NAFLD diagnosis and management.Adv Ther2021;38:2130-58 PMCID:PMC8107169

[4] Li, Rudolph E. Tanzi genetics of hidradenitis suppurativa.J Mol Genet2020;3:1-7

[5] Cummings JH.Denis Burkitt and the origins of the dietary fibre hypothesis.Nutr Res Rev2018;31:1-15

[6] Clark CG.Refined carbohydrate foods and disease. Some implications of dietary fibre.British Journal of Surgery1976;63:898

[7] O'keefe SJ.The association between dietary fibre deficiency and high-income lifestyle-associated diseases: Burkitt's hypothesis revisited.Lancet Gastroenterol Hepatol2019;4:984-96 PMCID:PMC6944853

[8] Stephen AM,Cloran SJ.Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health.Nutr Res Rev2017;30:149-90

[9] Shapiro H,Elinav E.Personalized microbiome-based approaches to metabolic syndrome management and prevention.J Diabetes2017;9:226-36

[10] Daack-Hirsch S,Jones K.All things considered, my risk for diabetes is medium: a risk personalization process of familial risk for type 2 diabetes.Health Expect2020;23:169-81 PMCID:PMC6978869

[11] Kim Y,D'Onofrio G,Safdar B.Patient ethnicity predicts poor health access and gaps in perception of personal cardiovascular risk factors.Crit Pathw Cardiol2017;16:147-57

[12] Ahlqvist E,Groop L.Subtypes of type 2 diabetes determined from clinical parameters.Diabetes2020;69:2086-93

[13] Ahlqvist E,Käräjämäki A.Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.Lancet Diabetes Endocrinol2018;6:361-9

[14] Zaharia OP,Strom A.Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study.Lancet Diabetes Endocrinol2019;7:684-94

[15] Fodor A,Suharoschi R,Roman G.Clinical and genetic predictors of diabetes drug's response.Drug Metab Rev2019;51:408-27

[16] Gallo M,De Cosmo S.Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey.BMJ Open Diabetes Res Care2015;3:e000109 PMCID:PMC4537916

[17] Strelitz J,Khunti K.Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: an observational analysis of the ADDITION-Europe trial.Diabetes Obes Metab2021;23:730-41

[18] Eiland L,Drincic A.Has technology improved diabetes management in relation to age, gender, and ethnicity?.Curr Diab Rep2019;19:111

[19] Cosentino F,Aboyans V.ESC Scientific Document Group2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.Eur Heart J2020;41:255-323

[20] Sun X,Yang X,Qiu X.From genetics and epigenetics to the future of precision treatment for obesity.Gastroenterol Rep (Oxf)2017;5:266-70 PMCID:PMC5691547

[21] Ge L,Ball GDC.Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials.BMJ2020;369:m696 PMCID:PMC7190064

[22] Lopez-Nava G,Storm AC.Personalization of endoscopic bariatric and metabolic therapies based on physiology: a prospective feasibility study with a single fluid-filled intragastric balloon.Obes Surg2020;30:3347-53

[23] Saigi-Morgui N,Bochud PY.Swiss Transplant Cohort StudyWeighted genetic risk scores and prediction of weight gain in solid organ transplant populations.PLoS One2016;11:e0164443 PMCID:PMC5082801

[24] Statistical fact sheet 2013 update. Available from: https://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_319576.pdf [Last accessed on 26 Jul 2021]

[25] Hayes SN.Preventing cardiovascular disease in women.Am Fam Physician2006;74:1331-40

[26] D'Agostino RB Sr,Pencina MJ.General cardiovascular risk profile for use in primary care: the Framingham Heart Study.Circulation2008;117:743-53

[27] Byrd JB.Personalized medicine and treatment approaches in hypertension: current perspectives.Integr Blood Press Control2016;9:59-67 PMCID:PMC4827884

[28] Melville S.Personalized medicine and the treatment of hypertension.Curr Hypertens Rep2019;21:13 PMCID:PMC6594382

[29] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[30] Yki-järvinen H.Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.Lancet Diabetes Endocrinol2014;2:901-10

[31] Lonardo A,Alswat KA.History of nonalcoholic fatty liver disease.Int J Mol Sci2020;21:5888 PMCID:PMC7460697

[32] Ratziu V.Why do so many NASH trials fail?.Gastroenterology2020;S0016-5085(20)30680

[33] Sharpton SR,Knight R.Current Concepts, Opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease.Cell Metab2021;33:21-32

[34] Christinat N,Masoodi M.Untargeted profiling of bile acids and lysophospholipids identifies the lipid signature associated with glycemic outcome in an obese non-diabetic clinical cohort.Biomolecules2020;10:1049 PMCID:PMC7407211

[35] Cespiati A,Tourna A.Genetics and epigenetics in the clinic: precision medicine in the management of fatty liver disease.Curr Pharm Des2020;26:998-1009

[36] Lorbek G,Rozman D.Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.Pharmacogenomics2016;17:1273-88

[37] Houghton D,Day CP.Gut microbiota and lifestyle interventions in NAFLD.Int J Mol Sci2016;17:447 PMCID:PMC4848903

[38] Luukkonen PK,Sädevirta S.Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.J Hepatol2016;64:1167-75

[39] Wainwright P.Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome.Int J Mol Sci2016;17:367 PMCID:PMC4813227

[40] Lonardo A,Targher G."Not all forms of NAFLD were created equal". Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?.Atherosclerosis2017;257:253-5

[41] Mauvais-jarvis F,Barnes PJ.Sex and gender: modifiers of health, disease, and medicine.Lancet2020;396:565-82 PMCID:PMC7440877

[42] Balakrishnan M,Dunn-Valadez S.Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2021;19:61-71.e15

[43] Lonardo A.Sexual Dimorphism of NAFLD in Adults. Focus on clinical aspects and implications for practice and translational research.J Clin Med2020;9:1278 PMCID:PMC7288212

[44] Lonardo A.Perspectives of nonalcoholic fatty liver disease research: a personal point of view.Explor Med2020;1:85-107

[45] Lonardo A.Renaming NAFLD to MAFLD: Could the LDE system assist in this transition?.J Clin Med2021;10:492 PMCID:PMC7866816

[46] Huang A.Healthinfo engineering. In: Management Association IR, editor. E-health and telemedicine. IGI Global; 2016. p. 537-50.

[47] Tayanloo-Beik A,Payab M.OMICS insights into cancer histology; Metabolomics and proteomics approach.Clin Biochem2020;84:13-20

[48] Vignoli A,McCartney A.Precision oncology via NMR-based metabolomics: a review on breast cancer.Int J Mol Sci2021;22:4687 PMCID:PMC8124948

[49] Liang L,Wang H.Metabolomics, metabolic flux analysis and cancer pharmacology.Pharmacol Ther2021;224:107827

[50] Yusof HM,Suddin LS,Mazlan M.Metabolomics profiling on different stages of colorectal cancer: a systematic review.Malays J Med Sci2018;25:16-34 PMCID:PMC6419892

[51] Salciccia S,Laganà A.Biomarkers in prostate cancer diagnosis: from current knowledge to the role of metabolomics and exosomes.Int J Mol Sci2021;22:4367 PMCID:PMC8122596

[52] Ahmed-Salim Y,Bracewell-Milnes T.The application of metabolomics in ovarian cancer management: a systematic review.Int J Gynecol Cancer2021;31:754-74

[53] Coelho M,Goodfellow BJ,Jones J.The potential of metabolomics in the diagnosis of thyroid cancer.Int J Mol Sci2020;21:5272 PMCID:PMC7432278

[54] Rawla P,Barsouk A.Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors.Prz Gastroenterol2019;14:89-103 PMCID:PMC6791134

[55] Lee J,Kim H.The relationship between metabolic syndrome and the incidence of colorectal cancer.Environ Health Prev Med2020;25:6 PMCID:PMC7031951

[56] Wani B,Ganaie MA.Metabolic syndrome and breast cancer risk.Indian J Med Paediatr Oncol2017;38:434-9 PMCID:PMC5759060

[57] McGrowder DA,Crawford TV.Prostate cancer and metabolic syndrome: is there a link?.Asian Pac J Cancer Prev2012;13:1-13

[58] Daniyal M,Akram M,Sultana S.Epidemiology, etiology, diagnosis and treatment of prostate cancer.Asian Pac J Cancer Prev2014;15:9575-8

[59] Lima AR,Amaro F,Carvalho M.Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics.Metabolites2021;11:181 PMCID:PMC8003702

[60] Craig ER,Norian LA.Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: a review.Gynecol Oncol2016;143:674-83 PMCID:PMC5689410

[61] Saorin A,Miolo G,Corona G.Emerging role of metabolomics in ovarian cancer diagnosis.Metabolites2020;10:419 PMCID:PMC7603269

[62] Ahmed-Salim Y,Bracewell-Milnes T.The application of metabolomics in ovarian cancer management: a systematic review.Int J Gynecol Cancer2021;31:754-74

[63] Park JH,Kim JH.Metabolic syndrome and the risk of thyroid cancer: a nationwide population-based cohort study.Thyroid2020;30:1496-504

[64] Huang LY,Chou P,Chu D.Thyroid fine-needle aspiration biopsy and thyroid cancer diagnosis: a nationwide population-based study.PLoS One2015;10:e0127354 PMCID:PMC4447367

[65] Pinchot SN,Schaefer S,Chen H.Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger.Arch Surg2009;144:649-55 PMCID:PMC2910711

[66] Pergola G, Silvestris F. Obesity as a major risk factor for cancer.J Obes2013;2013:291546

[67] Ottaiano A,Capozzi M.Obesity and cancer: biological links and treatment implications.Curr Cancer Drug Targets2018;18:231-8

[68] Pivetta E.The COVID-19 pandemic: a stress test for clinical epidemiology.Epidemiol Prev2020;44:28-9

[69] Peter S.Goodman SARS stung the global economy. The coronavirus is a greater menace.The New York Times2020;

[70] Targher G,Wang XB.Patients with diabetes are at higher risk for severe illness from COVID-19.Diabetes Metab2020;46:335-7 PMCID:PMC7255326

[71] Mantovani A,Zheng MH.Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies.Nutr Metab Cardiovasc Dis2020;30:1236-48 PMCID:PMC7258796

[72] Targher G,Byrne CD.Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.Gut2020;69:1545-7

[73] Gao F,Wang XB.Obesity is a risk factor for greater COVID-19 severity.Diabetes Care2020;43:e72-4

[74] Aghili SMM,Arjmand B.Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis.Int J Obes (Lond)2021;45:998-1016 PMCID:PMC7909378

[75] Sulli G,Taub PR.Training the circadian clock, clocking the drugs, and drugging the clock to prevent, manage, and treat chronic diseases.Trends Pharmacol Sci2018;39:812-27 PMCID:PMC7249726

[76] Raposo L,Ferreira D,Santos AC.Metabolic syndrome, thyroid function and autoimmunity - The PORMETS study.Endocr Metab Immune Disord Drug Targets2019;19:75-83 PMCID:PMC6340154

[77] da Rosa Franchi Santos LF,Costa Dall'Aqua LG.Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness, autoimmunity, metabolic syndrome and cortisol levels.Lupus2018;27:380-8

[78] Medina G,Peralta-Amaro AL.Metabolic syndrome, autoimmunity and rheumatic diseases.Pharmacol Res2018;133:277-88

[79] Ebrahimi M,Rezaiean S.Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity.Acta Cardiol2009;64:321-7